ArticleCalcified tissue international2025
Expanding the Genotypic and Phenotypic Spectrum of P3H1 Related Osteogenesis Imperfecta.
Article in Calcified tissue international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Non-COL1A1/2 genetic burden and osteoporosis-overlap in patients referred with osteogenesis imperfecta phenotype.Archives of osteoporosis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteogenesis Imperfecta (OI) is a genetically heterogeneous disorder with a clinical spectrum ranging from mild to severe. Biallelic P3H1 (OMIM*610339) variants are generally associated with a severe recessive phenotype. This study reports six individuals from three families with phenotypic variability and two novel variants, aiming to expand the phenotypic and genotypic spectrum of P3H1-related OI. The six patients from three unrelated families exhibited varying severity of P3H1-related OI. In Family 1, three siblings, all homozygous for the recurrent c.446 T > G (p.Leu149Arg) variant, showed marked phenotypic differences. One presented with a deforming phenotype, while the other two had milder forms with fewer fractures and little to no skeletal deformity. In Family 2, the affected individual had neonatal fractures and was compound heterozygous for a novel splice-site variant (c.1171-2_1171-1delinsC) and a missense change previously classified as variant of uncertain significance (VUS) (c.1224G > C; p.Lys408Asn). The variants were segregated confirming compound heterozygosity. In Family 3, two siblings with neonatal fractures were homozygous for a novel 58 bp deletion in exon 15 (c.2112_2169del; p.Glu708AlafsTer21), with both parents identified as carriers. This study expands the P3H1 genotypic spectrum with two novel variants and provides evidence supporting reclassification of c.1224G > C as likely pathogenic based on the updated PM3 criterion. It highlights phenotypic variability in patients with the same variant and suggests mild phenotypes may be seen in patients with certain P3H1 variants.
Indexed as
Identifiers
40762683What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.